Display options
Cite
West J, Cogan J, Geraci M, et al. Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC Med Genomics. 2008;1:45doi: 10.1186/1755-8794-1-45.
West, J., Cogan, J., Geraci, M., Robinson, L., Newman, J., Phillips, J. A., Lane, K., Meyrick, B., & Loyd, J. (2008). Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC medical genomics, 145. https://doi.org/10.1186/1755-8794-1-45
West, James, et al. "Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance." BMC medical genomics vol. 1 (2008): 45. doi: https://doi.org/10.1186/1755-8794-1-45
West J, Cogan J, Geraci M, Robinson L, Newman J, Phillips JA, Lane K, Meyrick B, Loyd J. Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC Med Genomics. 2008 Sep 29;1:45. doi: 10.1186/1755-8794-1-45. PMID: 18823550; PMCID: PMC2561034.
Copy Download .nbib Format: NLM
Share it on

BMC Med Genomics. 2008 Sep 29;1:45. doi: 10.1186/1755-8794-1-45.

Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance.

BMC medical genomics

James West, Joy Cogan, Mark Geraci, Linda Robinson, John Newman, John A Phillips, Kirk Lane, Barbara Meyrick, Jim Loyd

Affiliations

  1. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. [email protected]

PMID: 18823550 PMCID: PMC2561034 DOI: 10.1186/1755-8794-1-45

Abstract

BACKGROUND: While BMPR2 mutation strongly predisposes to pulmonary arterial hypertension (PAH), only 20% of mutation carriers develop clinical disease. This finding suggests that modifier genes contribute to FPAH clinical expression. Since modifiers are likely to be common alleles, this problem is not tractable by traditional genetic approaches. Furthermore, examination of gene expression is complicated by confounding effects attributable to drugs and the disease process itself.

METHODS: To resolve these problems, B-cells were isolated, EBV-immortalized, and cultured from familial PAH patients with BMPR2 mutations, mutation positive but disease-free family members, and family members without mutation. This allows examination of differences in gene expression without drug or disease-related effects. These differences were assayed by Affymetrix array, with follow-up by quantitative RT-PCR and additional statistical analyses.

RESULTS: By gene array, we found consistent alterations in multiple pathways with known relationship to PAH, including actin organization, immune function, calcium balance, growth, and apoptosis. Selected genes were verified by quantitative RT-PCR using a larger sample set. One of these, CYP1B1, had tenfold lower expression than control groups in female but not male PAH patients. Analysis of overrepresented gene ontology groups suggests that risk of disease correlates with alterations in pathways more strongly than with any specific gene within those pathways.

CONCLUSION: Disease status in BMPR2 mutation carriers was correlated with alterations in proliferation, GTP signaling, and stress response pathway expression. The estrogen metabolizing gene CYP1B1 is a strong candidate as a modifier gene in female PAH patients.

References

  1. N Engl J Med. 2001 Aug 2;345(5):319-24 - PubMed
  2. Nature. 2004 May 27;429(6990):446-52 - PubMed
  3. Am J Respir Crit Care Med. 2006 Apr 1;173(7):798-802 - PubMed
  4. Nat Genet. 2007 Oct;39(10):1202-7 - PubMed
  5. Am J Respir Crit Care Med. 2004 Oct 15;170(8):911-9 - PubMed
  6. Clin Chest Med. 2007 Mar;28(1):43-57, vii-viii - PubMed
  7. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):33S-39S - PubMed
  8. Adv Immunol. 2007;95:1-50 - PubMed
  9. Nucleic Acids Res. 2003 Jul 1;31(13):3483-6 - PubMed
  10. Nat Genet. 2000 Sep;26(1):81-4 - PubMed
  11. Chest. 2002 Mar;121(3 Suppl):104S-105S - PubMed
  12. Am J Respir Crit Care Med. 2006 Sep 1;174(5):590-8 - PubMed
  13. Ann Intern Med. 2008 Feb 19;148(4):278-83 - PubMed
  14. Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 - PubMed
  15. Bioinformatics. 2008 Jan 15;24(2):192-201 - PubMed
  16. Nat Genet. 1999 Jul;22(3):281-5 - PubMed
  17. Exp Lung Res. 2008 Aug;34(6):313-23 - PubMed
  18. J Biol Chem. 2007 Dec 21;282(51):37244-55 - PubMed
  19. Nucleic Acids Res. 2006 Jan 1;34(Database issue):D322-6 - PubMed
  20. Expert Opin Drug Metab Toxicol. 2005 Aug;1(2):187-202 - PubMed
  21. Respir Res. 2008;9:20 - PubMed
  22. N Engl J Med. 2002 Mar 21;346(12):933-5 - PubMed
  23. Am J Respir Crit Care Med. 2008 Jan 1;177(1):99-107 - PubMed
  24. Methods Mol Biol. 2000;132:365-86 - PubMed
  25. Surg Oncol. 1994 Jun;3(3):175-85 - PubMed
  26. Eur Respir J. 2002 Dec;20(6):1559-72 - PubMed
  27. J Autism Dev Disord. 2006 Nov;36(8):973-82 - PubMed
  28. Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9758-63 - PubMed
  29. Curr Opin Lipidol. 2007 Apr;18(2):187-93 - PubMed
  30. Am J Hum Genet. 2000 Sep;67(3):737-44 - PubMed
  31. Blood. 2002 Sep 1;100(5):1689-98 - PubMed
  32. Am J Med Genet B Neuropsychiatr Genet. 2008 Jul 5;147B(5):557-64 - PubMed
  33. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):210-9 - PubMed
  34. J Biochem Mol Toxicol. 1999;13(5):249-51 - PubMed
  35. Cancer Lett. 2005 Sep 28;227(2):115-24 - PubMed
  36. Circ Res. 2001 Mar 30;88(6):555-62 - PubMed
  37. Chest. 2002 Dec;122(6 Suppl):284S-286S - PubMed

Publication Types

Grant support